{
  "docId": "019de071-f579-76ad-bea5-b34da2c83a75",
  "docSlug": "563487226462eb4ab63630eb9b74a5cf",
  "documentTitle": "AstraZeneca | Investor Day Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 27,
  "pageCount": 42,
  "prevPage": 26,
  "nextPage": 28,
  "slideType": "before_after",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 7,
  "notes": "Uses a before-after framing to contrast the status quo (problem) with the new clinical solution.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-f579-76ad-bea5-b34da2c83a75/27",
  "deckHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75",
  "deckJsonHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75.json",
  "deckAnchorHref": "/decks/019de071-f579-76ad-bea5-b34da2c83a75#slide-27",
  "components": [
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.52,
        "y": 0.24
      },
      "kind": "list",
      "text": "TOPAZ-1 has practice-changing potential",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7fed52b2-fb11-40a5-9cdb-f141c16a882f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.45,
        "x": 0.05,
        "y": 0.24
      },
      "kind": "list",
      "text": "Lack of innovation in biliary tract cancer",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b1ea40d6-55f4-4dcd-82ea-5eab55dc572e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.05,
        "y": 0.57
      },
      "kind": "metric",
      "text": "75%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1da7355b-b2e3-4196-b721-0306511b21d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.05,
        "y": 0.31
      },
      "kind": "metric",
      "text": "10+ years",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6979243c-b38a-4760-8748-8e71a7e73cd6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.52,
        "y": 0.42
      },
      "kind": "metric",
      "text": "1 in 4",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c43ba44b-59b7-4123-b516-4bb4e5b7e893",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.15,
        "x": 0.05,
        "y": 0.44
      },
      "kind": "metric",
      "text": "5% to 15%",
      "attrs": null,
      "subkind": "big-number",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fb84ccf5-26f0-48b8-b84b-02ce2f7c4a3f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.96,
        "x": 0.02,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1. Turkes F, et al. Gastroenterol Res Pract. 2019; 2019:7698786. 2. Vienot A and Neuzillet C. Clin Res Hepatol Gastroenterol. 2020;44:810-824 3. Siegel R, et al. CA Cancer J Clin. 2020; 70: 7-30. and Nakachi K, et al. Japanese Journal of Clinical Oncology. 2018; 48(4): 392-395. and 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. AE = adverse events.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "599012c0-bcfb-432f-b229-3e2012c98944",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.94,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "TOPAZ-1 has the potential to become the first-ever IO therapy available for first-line, advanced biliary tract cancer patients",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "03104252-4f0f-48cb-a4d5-1af7bcc20f1b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "a0dd8fea-9927-4141-9f6b-b5665a4f0623",
      "evidence": "The slide presents a comparison between the current state and the potential future state of TOPAZ-1 as the first-ever IO therapy available for first-line, advanced biliary tract cancer patients.",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "a8bfe8c9-9851-406f-b0e1-656e08f697bb",
      "evidence": "Contrasts the 'Lack of innovation' (problem) with 'TOPAZ-1 has practice-changing potential' (solution).",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 32,
      "from": 26,
      "beatId": "b07cebc3-7a8b-44be-bf05-017bb65452c0",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "The deck concludes with a discussion of the commercial opportunity and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [
    {
      "to": 27,
      "from": 27,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "a8de0661-f386-49b5-a803-c3d99bc10bab",
      "evidence": "The deck presents TOPAZ-1 as a potential game-changer in GI cancers",
      "position": 0,
      "objective": "Highlight the potential of TOPAZ-1 to become the first-ever IO therapy for first-line, advanced biliary tract cancer patients",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 28,
      "from": 27,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "7271ea17-f681-46af-8e4d-590555fd889c",
      "evidence": "The deck presents HIMALAYA as an innovative IO regimen",
      "position": 1,
      "objective": "Show the potential of HIMALAYA to deliver survival benefit to patients with advanced, unresectable hepatocellular carcinoma",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}